Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pneumonia 1Lymphoma, Follicular 1Cytokine Release Syndrome 1COVID-19 1

Interventions

BNT162 Vaccine 22019-nCoV Vaccine mRNA-1273 2tocilizumab 1sotrovimab 1proxalutamide 1bemcentinib 1Therapeutics 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Patient Reported Outcome Measures 1Janus Kinase Inhibitors 1Influenza Vaccines 1Hydroxychloroquine 1HuMax-IL8 1Gelsolin 1Diagnostic Tests, Routine 1Decision Support Techniques 1COVID-19 Vaccines 1Blood Specimen Collection 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × COVID-19 × Gelsolin × Clear all
NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

BioAegis Therapeutics Inc.

Phase 2 Completed
64 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡